DCAT Value Chain Insights’ Production to Prescription
DCAT
52 episodes
1 week ago
Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
All content for DCAT Value Chain Insights’ Production to Prescription is the property of DCAT and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
Incorporating Sustainability into the Bio/Pharma Supply Chain: Where Does the Industry Stand?
DCAT Value Chain Insights’ Production to Prescription
15 minutes
3 years ago
Incorporating Sustainability into the Bio/Pharma Supply Chain: Where Does the Industry Stand?
A newly released DCAT benchmarking study examines the targets and progress made by bio/pharma companies and suppliers in reaching their sustainability goals. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Sustainability and the bio/pharma supply chainKey finding: External stakeholders drive effortsKey finding: Supply-chain sustainability lags internal effortsKey finding: Measuring achievement a major challengeK...
DCAT Value Chain Insights’ Production to Prescription
Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
